Research progress on the PI3K/AKT signaling pathway in gynecological cancer (Review)
Tóm tắt
Từ khóa
Tài liệu tham khảo
Zeng, 2018, Association between RAD51 135 G/C polymorphism and risk of 3 common gynecological cancers: A meta-analysis, Medicine (Baltimore), 97, e11251, 10.1097/MD.0000000000011251
Rodon, 2013, Development of PI3K inhibitors: Lessons learned from early clinical trials, Nat Rev Clin Oncol, 10, 143, 10.1038/nrclinonc.2013.10
Barra, 2019, Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer, Expert Opin Investig Drugs, 28, 131, 10.1080/13543784.2018.1558202
Lu, 2018, miR-338 modulates proliferation and autophagy by PI3K/AKT/mTOR signaling pathway in cervical cancer, Biomed Pharmacother, 105, 633, 10.1016/j.biopha.2018.06.024
Zhang, 2019, Tanshinone IIA induces apoptosis of ovarian cancer cells in vitro and in vivo through attenuation of PI3K/AKT/JNK signaling pathways, Oncol Lett, 17, 1896
Vanhaesebroeck, 2010, The emerging mechanisms of isoform-specific PI3K signalling, Nat Rev Mol Cell Biol, 11, 329, 10.1038/nrm2882
Guo, 2015, The PI3K/AKT pathway and renal cell carcinoma, J Genet Genomicsbao, 42, 343, 10.1016/j.jgg.2015.03.003
Osaki, 2004, PI3K-Akt pathway: Its functions and alterations in human cancer, Apoptosis, 9, 667, 10.1023/B:APPT.0000045801.15585.dd
Auger, 1989, PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells, Cell, 57, 167, 10.1016/0092-8674(89)90182-7
Ruderman, 1990, Activation of phosphatidylinositol 3-kinase by insulin, Proc Natl Acad Sci USA, 87, 1411, 10.1073/pnas.87.4.1411
Fruman, 2014, PI3K and cancer: Lessons, challenges and opportunities, Nat Rev Drug Discov, 13, 140, 10.1038/nrd4204
Samuels, 2006, Oncogenic PI3K and its role in cancer, Curr Opin Oncol, 18, 77, 10.1097/01.cco.0000198021.99347.b9
Engelman, 2009, Targeting PI3K signalling in cancer: Opportunities, challenges and limitations, Nat Rev Cancer, 9, 550, 10.1038/nrc2664
Vadas, 2011, Structural basis for activation and inhibition of class I phosphoinositide 3-kinases, Sci Signal, 4, re2, 10.1126/scisignal.2002165
Dbouk, 2013, Characterization of a tumor-associated activating mutation of the p110β PI 3-kinase, PLoS One, 8, e63833, 10.1371/journal.pone.0063833
Zhang, 2011, Structure of lipid kinase p110β/p85β elucidates an unusual SH2-domain-mediated inhibitory mechanism, Mol Cell, 41, 567, 10.1016/j.molcel.2011.01.026
Jaiswal, 2009, Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation, Cancer Cell, 16, 463, 10.1016/j.ccr.2009.10.016
Cheung, 2011, High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability, Cancer Discov, 1, 170, 10.1158/2159-8290.CD-11-0039
Sun, 2010, Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha, Proc Natl Acad Sci USA, 107, 15547, 10.1073/pnas.1009652107
Graupera, 2008, Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration, Nature, 453, 662, 10.1038/nature06892
Graupera, 2013, Regulation of angiogenesis by PI3K signaling networks, Exp Cell Res, 319, 1348, 10.1016/j.yexcr.2013.02.021
Hirsch, 2014, PI3K in cancer-stroma interactions: Bad in seed and ugly in soil, Oncogene, 33, 3083, 10.1038/onc.2013.265
Kinross, 2012, An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice, J Clin Invest, 122, 553, 10.1172/JCI59309
Toulany, 2017, Akt1 and Akt3 but not Akt2 through interaction with DNA-PKcs stimulate proliferation and post-irradiation cell survival of K-RAS-mutated cancer cells, Cell Death Discov, 3, 17072, 10.1038/cddiscovery.2017.72
Carnero, 2008, The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications, Curr Cancer Drug Targets, 8, 187, 10.2174/156800908784293659
Tokunaga, 2008, Deregulation of the Akt pathway in human cancer, Curr Cancer Drug Targets, 8, 27, 10.2174/156800908783497140
Manning, 2017, AKT/PKB signaling: Navigating the network, Cell, 169, 381, 10.1016/j.cell.2017.04.001
Alessi, 1997, Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha, Curr Biol, 7, 261, 10.1016/S0960-9822(06)00122-9
Andjelković, 1997, Role of translocation in the activation and function of protein kinase B, J Biol Chem, 272, 31515, 10.1074/jbc.272.50.31515
Girardi, 2014, Differential phosphorylation of Akt1 and Akt2 by protein kinase CK2 may account for isoform specific functions, Biochim Biophys Acta, 1843, 1865, 10.1016/j.bbamcr.2014.04.020
Thorpe, 2015, PI3K in cancer: Divergent roles of isoforms, modes of activation and therapeutic targeting, Nat Rev Cancer, 15, 7, 10.1038/nrc3860
Wong, 2010, Targeting the PI3K signaling pathway in cancer, Curr Opin Genet Dev, 20, 87, 10.1016/j.gde.2009.11.002
Carpten, 2007, A transforming mutation in the pleckstrin homology domain of AKT1 in cancer, Nature, 448, 439, 10.1038/nature05933
Mazloumi Gavgani, 2018, Class I phosphoinositide 3-Kinase PIK3CA/p110α and PIK3CB/p110β isoforms in endometrial cancer, Int J Mol Sci, 19, E3931, 10.3390/ijms19123931
Prat, 2007, Endometrial carcinoma: Pathology and genetics, Pathology, 39, 72, 10.1080/00313020601136153
Lee, 2018, Metformin as a therapeutic target in endometrial cancers, Front Oncol, 8, 341, 10.3389/fonc.2018.00341
Hua, 2017, PI3K/AKT/mTOR pathway promotes progestin resistance in endometrial cancer cells by inhibition of autophagy, Onco Targets Ther, 10, 2865, 10.2147/OTT.S95267
Lu, 2008, Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma, Clin Cancer Res, 14, 2543, 10.1158/1078-0432.CCR-07-0321
Shen, 2010, Morphoproteomic analysis reveals an overexpressed and constitutively activated phospholipase D1-mTORC2 pathway in endometrial carcinoma, Int J Clin Exp Pathol, 4, 13
Cancer Genome Atlas Research Network, 2013, Integrated genomic characterization of endometrial carcinoma, Nature, 497, 67, 10.1038/nature12113
Shi, 2018, Bone marrow mesenchymal stem cell-derived exosomal miR-21 protects C-kit+ cardiac stem cells from oxidative injury through the PTEN/PI3K/Akt axis, PLoS One, 13, e0191616, 10.1371/journal.pone.0191616
Pavlidou, 2014, Molecular alterations of PI3K/Akt/mTOR pathway: A therapeutic target in endometrial cancer, ScientificWorldJournal, 2014, 709736, 10.1155/2014/709736
Sun, 2001, Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia, Am J Clin Pathol, 115, 32, 10.1309/7JX6-B9U9-3P0R-EQNY
Kanamori, 2001, Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma, Clin Cancer Res, 7, 892
Kong, 1997, PTEN1 is frequently mutated in primary endometrial carcinomas, Nat Genet, 17, 143, 10.1038/ng1097-143
Quddus, 2009, Utility of PTEN expression of endometrial ‘surface epithelial changes’ and underlying atypical endometrial hyperplasia, Int J Gynecol Pathol, 28, 471, 10.1097/PGP.0b013e3181a06f96
Mutter, 2001, Pten, a protean tumor suppressor, Am J Pathol, 158, 1895, 10.1016/S0002-9440(10)64656-1
Bansal, 2009, The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies, Cancer Control, 16, 8, 10.1177/107327480901600102
Bertelsen, 2006, Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: Frequent PIK3CA amplification and AKT phosphorylation, Int J Cancer, 118, 1877, 10.1002/ijc.21461
Oh, 2006, Deregulation of eIF4E: 4E-BP1 in differentiated human papillomavirus-containing cells leads to high levels of expression of the E7 oncoprotein, J Virol, 80, 7079, 10.1128/JVI.02380-05
Schwarz, 2012, Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical cancer, Clin Cancer Res, 18, 1464, 10.1158/1078-0432.CCR-11-2485
Rashmi, 2014, AKT inhibitors promote cell death in cervical cancer through disruption of mTOR signaling and glucose uptake, PLoS One, 9, e92948, 10.1371/journal.pone.0092948
Isakoff, 2005, Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells, Cancer Res, 65, 10992, 10.1158/0008-5472.CAN-05-2612
Bader, 2006, Cancer-specific mutations in PIK3CA are oncogenic in vivo, Proc Natl Acad Sci USA, 103, 1475, 10.1073/pnas.0510857103
Zhao, 2005, The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells, Proc Natl Acad Sci USA, 102, 18443, 10.1073/pnas.0508988102
Gymnopoulos, 2007, Rare cancer-specific mutations in PIK3CA show gain of function, Proc Natl Acad Sci USA, 104, 5569, 10.1073/pnas.0701005104
Ocana, 2014, Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: Systematic review and meta-analysis, PLoS One, 9, e95219, 10.1371/journal.pone.0095219
Grigsby, 2017, Clinical outcomes and differential effects of PI3K pathway mutation in obese versus non-obese patients with cervical cancer, Oncotarget, 9, 4061, 10.18632/oncotarget.23664
Bosch, 2002, The causal relation between human papillomavirus and cervical cancer, J Clin Pathol, 55, 244, 10.1136/jcp.55.4.244
Libby, 2009, New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes, Diabetes Care, 32, 1620, 10.2337/dc08-2175
Eskander, 2014, Exploiting the therapeutic potential of the PI3K-AKT-mTOR pathway in enriched populations of gynecologic malignancies, Expert Rev Clin Pharmacol, 7, 847, 10.1586/17512433.2014.968554
Ko, 2003, Identification and differential expression of novel human cervical cancer oncogene HCCR-2 in human cancers and its involvement in p53 stabilization, Oncogene, 22, 4679, 10.1038/sj.onc.1206624
Cho, 2006, The phosphatidylinositol 3-kinase/Akt pathway regulates the HCCR-1 oncogene expression, Gene, 384, 18, 10.1016/j.gene.2006.07.006
Gui, 2012, The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer, Cancer Epidemiol, 36, 490, 10.1016/j.canep.2012.06.005
Mabuchi, 2015, The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer, Gynecol Oncol, 137, 173, 10.1016/j.ygyno.2015.02.003
Levine, 2005, Frequent mutation of the PIK3CA gene in ovarian and breast cancers, Clin Cancer Res, 11, 2875, 10.1158/1078-0432.CCR-04-2142
Andorfer, 2016, Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer, BMC Syst Biol, 10, 33, 10.1186/s12918-016-0278-z
Cheaib, 2015, The PI3K/Akt/mTOR pathway in ovarian cancer: Therapeutic opportunities and challenges, Chin J Cancer, 34, 4, 10.5732/cjc.014.10289
Mabuchi, 2009, mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary, Clin Cancer Res, 15, 5404, 10.1158/1078-0432.CCR-09-0365
Di Nicolantonio, 2010, Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus, J Clin Invest, 120, 2858, 10.1172/JCI37539
Altomare, 2004, AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth, Oncogene, 23, 5853, 10.1038/sj.onc.1207721
Borman, 2000, Ovotoxicity in female Fischer rats and B6 mice induced by low-dose exposure to three polycyclic aromatic hydrocarbons: Comparison through calculation of an ovotoxic index, Toxicol Appl Pharmacol, 167, 191, 10.1006/taap.2000.9006
Sobinoff, 2012, Staying alive: PI3K pathway promotes primordial follicle activation and survival in response to 3MC-induced ovotoxicity, Toxicol Sci, 128, 258, 10.1093/toxsci/kfs137
Cancer Genome Atlas Research Network, 2011, Integrated genomic analyses of ovarian carcinoma, Nature, 474, 609, 10.1038/nature10166
Dobbin, 2013, The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer, Int J Mol Sci, 14, 8213, 10.3390/ijms14048213
Cho, 2013, Novel targeting of phosphatidylinositol 3-kinase and mammalian target of rapamycin in renal cell carcinoma, Cancer J, 19, 311, 10.1097/PPO.0b013e31829d5cea
O'Reilly, 2006, mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt, Cancer Res, 66, 1500, 10.1158/0008-5472.CAN-05-2925
Figlin, 2013, Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: New strategies for overcoming resistance to VEGFR and mTORC1 inhibitors, Int J Cancer, 133, 788, 10.1002/ijc.28023
Dillon, 2009, Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression, Cancer Res, 69, 5057, 10.1158/0008-5472.CAN-08-4287
Endersby, 2011, Nonredundant functions for Akt isoforms in astrocyte growth and gliomagenesis in an orthotopic transplantation model, Cancer Res, 71, 4106, 10.1158/0008-5472.CAN-10-3597
Behbakht, 2011, Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A gynecologic oncology group study, Gynecol Oncol, 123, 19, 10.1016/j.ygyno.2011.06.022
Takano, 2011, Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: A report of six cases, Int J Clin Oncol, 16, 605, 10.1007/s10147-010-0177-z
Pétignylechartier, 2017, The mTORC1/2 Inhibitor AZD8055 strengthens the efficiency of the mek inhibitor trametinib to reduce the Mcl-1/[Bim and Puma] ratio and to sensitize ovarian carcinoma cells to ABT-737, Mol Cancer Ther, 16, 102, 10.1158/1535-7163.MCT-16-0342
Itamochi, 2017, Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma, Br J Cancer, 117, 717, 10.1038/bjc.2017.228
Slomovitz, 2012, The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer, Clin Cancer Res, 18, 5856, 10.1158/1078-0432.CCR-12-0662
Sahoo, 2018, Adipose-Derived VEGF-mTOR signaling promotes endometrial hyperplasia and cancer: Implications for obese women, Mol Cancer Res, 16, 309, 10.1158/1541-7786.MCR-17-0466
Philip, 2017, Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors, BMC Cancer, 17, 638, 10.1186/s12885-017-3639-0
Han, 2018, Novel targeted therapies in ovarian and uterine carcinosarcomas, Discov Med, 25, 309
Tamura, 2018, Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions, Oncogenesis, 7, 4, 10.1038/s41389-017-0018-2
Carneiro, 2015, FGFR3-TACC3: A novel gene fusion in cervical cancer, Gynecol Oncol Rep, 13, 53, 10.1016/j.gore.2015.06.005